Amarin’s Vazkepa gets green light from SMC
Treatment will help reduce the risk of heart attacks and strokes for patients across Scotland
Read Moreby John Pinching | Aug 9, 2023 | News | 0
Treatment will help reduce the risk of heart attacks and strokes for patients across Scotland
Read Moreby John Pinching | Apr 11, 2023 | News | 0
Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer
Read Moreby John Pinching | Jan 18, 2023 | News | 0
Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients
Read Moreby John Pinching | Dec 13, 2022 | News | 0
Therapy will now treat adults across Scotland with moderate rheumatoid arthritis
Read Moreby John Pinching | Nov 8, 2022 | News | 0
New access to treatment involves adult patients with hyperkalaemia across Scotland
Read Moreby John Pinching | Sep 14, 2022 | News | 0
Therapy is for the treatment of spasticity due to multiple sclerosis
Read Moreby John Pinching | Aug 10, 2022 | News | 0
Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the UK
Read Moreby John Pinching | Jun 6, 2022 | News | 0
New facility opens on the Cambridge Research Park offering sterile finish
Read Moreby John Pinching | Mar 9, 2022 | News | 0
Trodelvy is accepted for use in mTNBC patients who have already received two or more systemic therapies
Read Moreby Lucy Parsons | Jul 13, 2021 | News | 0
SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
Read Moreby Lucy Parsons | Jun 8, 2021 | News | 0
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
Read Moreby Lucy Parsons | May 11, 2021 | News | 0
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
